Inverness Medical Innovations

Alere President and CEO Ron Zwanziger last week provided investors with an update on the development timeline for a pair of point-of-care nucleic acid testing plartforms, the company's first molecular diagnostics products.

Health management-services and diagnostics firm Alere is developing a pair of nucleic acid testing platforms, representing the company's first major move into the molecular diagnostics space, according to recent company presentations.

In clinical studies, the test demonstrated 97.1 percent positive agreement and 100 percent negative agreement with conventional methods of testing for MRSA, AdvanDx said.

Inverness will sell the real-time PCR assay in Germany, Austria, and Switzerland.

The UK-based company also signed on Inverness Medical Canada to distribute its products in the country.

Inverness, through its Biosite division, will develop and evaluate tests using Miraculins' panel of 35 biomarkers for placenta development and preeclampsia.

In an SEC filing, Thermo Fisher said that it believes the termination results from its recent decision to expand its diagnostics portfolio. Among Biosite's products are protein-based tests for congestive heart failure and cardiovascular diseases.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.